Human MIP-3 alpha (CCL20) Recombinant
$70.00 – $2,700.00
| accession | P78556 |
| Source | Optimized DNA sequence encoding Human MIP-3 alpha (CCL20) mature chain was expressed in Escherichia Coli. |
| Molecular weight | Human CCL20, generated by the proteolytic removal of the signal peptide and propeptide and has a calculated molecular mass of approximately8 kDa. RecombinantCCL-20 is a monomeric protein consisting of amino acid residue subunits and migrates as an approximately8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. |
| Purity | >98%, as determined by SDS-PAGE and HPLC |
| Biological Activity | Determined by its ability to chemoattract human monocytes using a concentration range of.0-40.0 ng/ml. |
| Protein Sequence | MCCTKSLLLA ALMSVLLLHL CGESEAASNF DCCLGYTDRI LHPKFIVGFT RQLANEGCDI NAIIFHTKKK LSVCANPKQT WVKYIVRLLS KKVKNM |
| Endotoxin | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg). |
| Presentation | Recombinant CCL20 was lyophilized from a.2 μm filteredmM PB,100mM NaCl solution pH.5. |
| Reconstitution | A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers. |
| Storage | The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles. |
| Usage | This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes. |
| Interactor | P51684 |
| Biological Process | Chemotaxis |
| Biological Process | Inflammatory-response |
| Molecular function | Antimicrobial |
| Molecular function | Cytokine |
Methods
Expression of CCR6/CCL20 in NSCLC tissue samples.
|
Langerin-positive cells and CCL20 expression are reduced in lesional skin of EV patients.
|
Langerin-positive cells and CCL20 expression are reduced in lesional skin of EV patients.
|